Exact Sciences Corp. (NSDQ:EXAS) filed a shelf registration statement for the sale of up to $150 million in equity, debt and warrants, according to the federal Securities & Exchange Commission.
In a press release, the Madison, Wis.-based molecular diagnostics developer said it does not have immediate plans to offer the securites, but wants to keep its options open.
Exact said use of proceeds from the sale of any securities will, at the time of any offering, be detailed in a supplement to the prospectus that the company filed for the shelf registration.
Exact Sciences’ net losses for its 2010 second quarter were almost double the company’s revenues, but still less than during the same period last year.
